- Home
- THQ vs IVA Comparison
THQ vs IVA Comparison
Compare THQ & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THQ | IVA |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.1M | 804.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | THQ | IVA |
|---|---|---|
| Price | $19.87 | $7.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 158.9K | ★ 546.8K |
| Earning Date | 01-01-0001 | 09-29-2025 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,929,536.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.29 | $2.14 |
| 52 Week High | $20.38 | $7.98 |
Technical Indicators
Market Signals| Indicator | THQ | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 80.96 |
| Support Level | $19.50 | $5.92 |
| Resistance Level | $20.39 | $6.66 |
| Average True Range (ATR) | 0.34 | 0.34 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 62.32 | 96.23 |
Price Performance
Historical ComparisonAbout THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.